Brief: Propanc Biopharma prepares orphan drug application for ovarian cancer drug
02/08/2017 13:30
Aug 2 (Reuters) - Propanc Biopharma Inc PPCB.PK
* Company prepares orphan drug designation application to
FDA for treatment of ovarian cancer
Source text for Eikon: ID:nMKWR7Qjya
Further company coverage: PPCB.PK
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Propanc Biopharma
See all newsNASDAQ TRADE HALT HALT NEWS PENDING AT 09:29 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition With Prp In Pancreatic Cancer Models, Contrasting Profile With Revolution Medicines’ Daraxonrasib
Brief: Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common Stock - SEC Filing
Brief: Propanc Biopharma To File Cta In Australia For Phase 1B Study In 30–40 Advanced Cancer Patients